Astria Therapeutics, Inc. (ATXS)
| Previous close | 3.8900 |
| Open | 3.7800 |
| Bid | 3.5000 x 900 |
| Ask | 3.6200 x 800 |
| Day's range | 3.5000 - 3.9250 |
| 52-week range | 3.5000 - 15.7200 |
| Volume | |
| Avg. volume | 18,937 |
| Market cap | 45.82M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.7430 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.60 |
- Business Wire
Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
BOSTON, May 12, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
- Business Wire
Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference
BOSTON, April 21, 2022--Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in a presentation titled "Development of STAR-0215: An Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE" at the 2022 Fc Receptor a
- Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 04, 2022--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted equity awards on April 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astr
